Valuation: Nektar Therapeutics

Market Cap 2.31B 2.02B 1.87B 1.72B 3.24B 222B 3.29B 22.34B 8.76B 109B 8.66B 8.47B 375B P/E 2026 *
-7.61x
P/E 2027 * -6.19x
Enterprise Value 2.31B 2.02B 1.87B 1.72B 3.24B 222B 3.29B 22.34B 8.76B 109B 8.66B 8.47B 375B EV / Sales 2026 *
56x
EV / Sales 2027 * 62.5x
Free-Float
99.55%
Yield 2026 *
-
Yield 2027 * -
1 day-3.68%
1 week-3.51%
Current month-5.57%
1 month+0.34%
3 months-34.30%
6 months+81.96%
Current year+55.92%
1 week 64.46
Extreme 64.46
69.52
1 month 61.29
Extreme 61.29
77.23
Current year 33.4
Extreme 33.4
109
1 year 21.02
Extreme 21.02
109
3 years 6.19
Extreme 6.189
109
5 years 6.19
Extreme 6.189
290.55
10 years 6.19
Extreme 6.189
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 2006-12-31
Director of Finance/CFO 60 2026-05-14
Chief Tech/Sci/R&D Officer 52 2015-06-30
Director TitleAgeSince
Director/Board Member 72 2000-07-31
Chairman 69 1992-04-30
Director/Board Member 73 2007-01-31
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Sell

Chief Technology Officer

-5,681 0.0168%
6/17/26 Sell

Chief Executive Officer

-10,000 0.0296%
6/15/26 Sell

Chief Technology Officer

-5,538 0.0164%
Change 5-day change 1-year change 3-year change Capi.($)
-3.71%-3.51%+165.93%+699.09% 2.31B
+0.21%-0.79%+56.02%+57.39% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
+0.33%-0.14%+6.04%+411.93% 23.48B
+0.83%+2.50%-15.23%-14.29% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-2.97%+32.73%-33.30% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
+0.72%+0.56%+27.33%+183.62% 14.06B
Average +0.80%-2.49%+55.09%+233.13% 23.59B
Weighted average by Cap. +1.67%-2.35%+43.94%+146.05%

Financials

2026 *2027 *
Net sales 41.22M 36.13M 33.4M 30.71M 57.95M 3.97B 58.88M 399M 157M 1.94B 155M 151M 6.7B 36.91M 32.35M 29.9M 27.5M 51.89M 3.56B 52.72M 358M 140M 1.74B 139M 136M 6B
Net income -249M -218M -201M -185M -349M -23.97B -355M -2.41B -944M -11.73B -933M -913M -40.4B -355M -311M -288M -265M -499M -34.24B -507M -3.44B -1.35B -16.75B -1.33B -1.3B -57.72B
Net Debt - -
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
26-07-20 US$65.92 -3.43% 213,379
26-07-17 US$68.26 +1.80% 538,398
26-07-16 US$67.05 -1.83% 746,227
26-07-15 US$68.30 +1.68% 543,479
26-07-14 US$67.17 -1.68% 814,761
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
68.26USD
Average target price
153.25USD
Spread / Average Target
+124.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock